Study of metreleptin for partial lipodystrophy
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests an open-label study of metreleptin in people with partial lipodystrophy, a condition where fat is lost from some areas of the body. The goal is to see if the drug can help manage related health problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with either inherited (familial) or acquired partial lipodystrophy.
- You cannot have received any experimental treatment in the last 6 months or longer, depending on the drug's half-life.
- There may be other criteria that the study doctor will check.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry follows people who are already taking metreleptin (a medicine for certain rare conditions) to better understand its long-term safety and how well it works in everyday use. It may help you and other patients by building real-world evidence about this treatment.
This Phase 2 study tests pegvisomant, a medicine that blocks growth hormone, to see if it can improve severe insulin resistance in people with a specific genetic cause or a rare fat distribution condition. If you fit the rare diagnosis, the study may help clarify whether growth-hormone blocking can improve blood sugar and related health markers.
This study tests the long-term safety of metreleptin for people with partial lipodystrophy. It is for those who already completed a related study and want to continue treatment.
This study looks at how pregnancy goes and what birth outcomes happen in women with lipodystrophy, comparing those who used metreleptin during pregnancy versus those who did not. It also collects information and blood samples from the children so researchers can better understand the effects of metreleptin during pregnancy.
This trial is testing a medication called tirzepatide (Mounjaro) to see if it can help people with a rare fat disorder called familial partial lipodystrophy. The study hopes to improve blood sugar control and lower triglycerides, which are often high in this condition.
This trial studies whether a low-calorie (low energy) diet can improve diabetes control in adults with familial partial lipodystrophy. It likely helps by changing how your body handles blood sugar and fat use, but you must meet specific safety and eligibility checks.
Hear when a new Partial Lipodystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.